Skip to main content
Premium Trial:

Request an Annual Quote

Isis, Biogen Idec Ink Antisense Drug-Development Partnership

Premium

Isis Pharmaceuticals said this week that it has teamed with Biogen Idec to develop antisense-based drugs for neurological and neuromuscular disorders.

Isis will receive an upfront payment of $30 million, and is responsible for discovering a lead antisense drug for three undisclosed targets. Isis will be responsible for developing the drugs through phase II testing, and Biogen Idec will have the option to license the compounds until this point.

Isis stands to receive additional research and development support prior to the exercise of the options, and could receive an additional $200 million in license fees and regulatory milestones per target. It will also receive double-digit royalties on drug sales.

If Biogen Idec exercises its options, it will take over all development and commercialization responsibilities for the compounds.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.